Improving survival in the 6 months after diagnosis of heart failure in the past decade: population-based data from the UK.

Imperial College, London, UK.
Heart (British Cardiac Society) (Impact Factor: 5.01). 08/2009; 95(22):1851-6. DOI: 10.1136/hrt.2008.156034
Source: PubMed

ABSTRACT To investigate the secular trend in survival after a new diagnosis of heart failure in the UK population.
Comparison of all-cause mortality in the 6 months after diagnosis of heart failure in population-based studies in the south east of England in 2004-5 (Hillingdon-Hastings Study) and 1995-7 (Hillingdon-Bromley Studies).
396 patients in the 2004-5 cohort and 552 patients in the 1995-7 cohort with incident (new) heart failure.
All-cause mortality.
All-cause mortality rates were 6% (95% CI 3% to 8%) at 1 month, 11% (8% to 14%) at 3 months and 14% (11% to 18%) at 6 months in the 2004-5 cohort compared with 16% (13% to 20%), 22% (19% to 25%) and 26% (22% to 29%), respectively, in the 1995-7 cohort (difference between the two cohorts, p<0.001). The difference in survival was not explained by any difference in the demographics or severity of heart failure at presentation. There was a difference at baseline and thereafter in the use of neurohormonal antagonists (beta-blockers and angiotensin-converting enzyme inhibitors).
Although early mortality remains high among patients with newly diagnosed heart failure in the UK general population, there is strong evidence of a marked improvement in survival from 1995-7 to 2004-5, perhaps partly explained by an increased usage of neurohormonal antagonists.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Heart failure (HF) is a clinical syndrome and not a stand-alone diagnosis – identification of the aetiology of the underlying cardiac abnormality and the whole body’s response to it is key to providing optimal management of the individual patient. The classic triad of clinical features – breathlessness, fatigue and fluid retention – can be the result of any disorder (genetic or acquired) affecting the structure or function of the heart in a manner that impairs its ability to act as an efficient pump. Despite improved understanding of the pathophysiology, and a wider range of therapeutic options, HF remains a serious condition with considerable morbidity and mortality. It is a global problem, though the relative importance of different aetiologies differs between the developed world – where the syndrome is most commonly a consequence of ischaemic heart disease – and the developing world, where rheumatic fever remains an important cause. HF can present either de novo, as a consequence of acute myocardial insult, or in its chronic form, where decompensation secondary to coincident medical problems often requires acute management. The HF syndrome is characterized by cardiac dysfunction with haemodynamic, renal and neurohormonal changes attempting to maintain circulatory homeostasis. Ultimately, such changes are maladaptive and result in excessive sodium and fluid retention, changes in muscle blood flow, altered breathing pattern, arrhythmia, and an inflammatory state with immune activation. Current evidence-based therapies ameliorate these responses and improve survival and quality of life.
    Medicine. 01/2010; 38(9):467-472.
  • [Show abstract] [Hide abstract]
    ABSTRACT: A recent randomized placebo-controlled clinical trial has reported reductions in mortality and hospitalizations in patients with chronic heart failure (CHF) who were prescribed highly purified omega-3 polyunsaturated fatty acid ethyl esters (n-3 PUFA). This study aimed at evaluating the cost and benefits associated with their use in the treatment of CHF in a UK setting. Results from a recent clinical trial were used to develop a Markov model to project clinical outcomes while capturing relevant costs and patient quality of life. The model captured outcomes over a lifetime horizon from a UK National Health Service perspective, with direct costs accounted in 2009 GBP (£) and discounted at 3.5% together with clinical benefits. Results are presented in terms of life expectancy, quality-adjusted life expectancy, direct costs, and incremental cost-effectiveness ratios. In addition to standard therapy, n-3 PUFA vs. placebo increased lifetime direct costs by £993 (≈€1150), with additional quality-adjusted life expectancy of 0.079 quality-adjusted life years (QALYs), and mean lifetime costs of £12,636 (≈€14,600) per QALY gained. Probabilistic sensitivity analyses suggested a 60% likelihood of n-3 PUFA being regarded as cost-effective versus placebo at a willingness-to-pay threshold of £30,000 (≈€34,600) per QALY gained. By currently accepted standards of value for money in the UK; the addition of n-3 PUFA to optimal medical therapy for patients with heart failure is likely to be cost-effective.
    European Journal of Heart Failure 06/2011; 13(6):681-9. · 5.25 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To explore the effect contact with a heart failure nurse can have on patients' illness beliefs, mood and quality of life.
    Journal of Clinical Nursing 06/2014; · 1.32 Impact Factor